Merrimack Agrees To Sell Ipsen Cancer Drugs In $1.03B Deal
Pancreatic cancer drug maker Merrimack Pharmaceuticals Inc. continued its restructuring efforts on Sunday with an agreement to sell two of its cancer drugs to Ipsen in a deal that could be...To view the full article, register now.
Already a subscriber? Click here to view full article